Other markers often used as a surrogate for responses to checkpoint inhibitors like PD1-positive CD4 or CD8 T cells were higher in the order relapsed AML > newly diagnosed AML > HD (p < 0.01). The gene discussed is CD8A; the disease is acute myeloid leukemia.